Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Acrivon Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 40 | 43 | +3 |
| Shares | 15.1M | 15.1M | −32.7K (−0.2%) |
| Value | $196.0M | $144.3M | −$51.7M (−26.4%) |
New holders (4)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Allspring Global Investments Holdings, LLC | 1,564 | $15.0K | 0.00% |
| Qube Research & Technologies Ltd | 138 | $1.32K | 0.00% |
| Toronto Dominion Bank | 41 | $392 | 0.00% |
| Nisa Investment Advisors, LLC | 12 | $115 | 0.00% |
Sold out (1)
Institutions that held Acrivon Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Deutsche Bank AG | 4,062 | $52.6K |